Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EBT (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed EBT for 9 consecutive years, with -$11.2 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 50.73% to -$11.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.7 million, a 94.64% increase, with the full-year FY2025 number at -$3.7 million, up 94.64% from a year prior.
  • EBT was -$11.2 million for Q4 2025 at Akebia Therapeutics, down from $1.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $29.0 million in Q2 2022 to a low of -$84.3 million in Q2 2021.
  • A 5-year average of -$25.3 million and a median of -$16.2 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: soared 134.44% in 2022, then tumbled 3814.01% in 2024.
  • Akebia Therapeutics' EBT stood at -$70.4 million in 2021, then skyrocketed by 90.76% to -$6.5 million in 2022, then skyrocketed by 109.44% to $614000.0 in 2023, then crashed by 3814.01% to -$22.8 million in 2024, then soared by 50.73% to -$11.2 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's EBT are -$11.2 million (Q4 2025), $1.2 million (Q3 2025), and $247000.0 (Q2 2025).